Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

XtalPi Closes $15 Million for AI-Aided Drug Design

publication date: Jan 24, 2018

XtalPi of Boston and Shenzhen has closed a $15 million Series B funding led by Sequoia China, with participation from Google's  venture arm and existing investor Tencent. XtalPi combines artificial intelligence, quantum physics, and high-performance cloud computing to aid in drug design. The company believes its proprietary algorithms can predict important characteristics of small molecule drug candidates, saving development time. So far, XtalPi has raised over $20 million. More details....

Stock Symbols: (NSDQ: GOOG) (HK: 0700)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China